| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Victor Lasebikan, Olaolu O Arem. Cannabis Use and Associated Harms among Schizophrenia Patients in a Nigerian Clinical Setting: A Case-Control Study. Frontiers in psychiatry. vol 7. 2016-08-18. PMID:27536254. |
cannabis use and associated harms among schizophrenia patients in a nigerian clinical setting: a case-control study. |
2016-08-18 |
2023-08-13 |
Not clear |
| Victor Lasebikan, Olaolu O Arem. Cannabis Use and Associated Harms among Schizophrenia Patients in a Nigerian Clinical Setting: A Case-Control Study. Frontiers in psychiatry. vol 7. 2016-08-18. PMID:27536254. |
the overall aim of this study was to determine the prevalence of cannabis use among patients with schizophrenia with associated levels of harm in a nigerian clinical setting. |
2016-08-18 |
2023-08-13 |
Not clear |
| Marc W Manseau, Donald C Gof. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 12. issue 4. 2016-07-22. PMID:26311150. |
cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. |
2016-07-22 |
2023-08-13 |
human |
| Marc W Manseau, Donald C Gof. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 12. issue 4. 2016-07-22. PMID:26311150. |
schizophrenia that develops after cannabis use may have a unique clinical phenotype, and several genetic polymorphisms may modulate the relationship between cannabis use and psychosis. |
2016-07-22 |
2023-08-13 |
human |
| Marc W Manseau, Donald C Gof. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 12. issue 4. 2016-07-22. PMID:26311150. |
the endocannabinoid system has been implicated in psychosis both related and unrelated to cannabis exposure, and studying this system holds potential to increase understanding of the pathophysiology of schizophrenia. |
2016-07-22 |
2023-08-13 |
human |
| Marc W Manseau, Donald C Gof. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 12. issue 4. 2016-07-22. PMID:26311150. |
Δ(9)-tetrahydrocannabinol in cannabis can cause symptoms of schizophrenia when acutely administered, and cannabidiol (cbd), another compound in cannabis, can counter many of these effects. |
2016-07-22 |
2023-08-13 |
human |
| K Croaker, R Langdo, P War. The neuropsychological consequences of cannabis use in schizophrenia: a preliminary analysis. Acta neuropsychiatrica. vol 18. issue 6. 2016-07-12. PMID:27397264. |
the neuropsychological consequences of cannabis use in schizophrenia: a preliminary analysis. |
2016-07-12 |
2023-08-13 |
Not clear |
| M Cohen, V Carr, P B Ward, T Ehlkes, P Johnston, R Thienel, U Schal. 01-03 fMRI in schizophrenia and cannabis users. Acta neuropsychiatrica. vol 18. issue 6. 2016-07-12. PMID:27397344. |
01-03 fmri in schizophrenia and cannabis users. |
2016-07-12 |
2023-08-13 |
Not clear |
| C Loughland, K McCabe, S Quinn, M Hunter, T Lewi. 01-04 Visual scanpath comparisons between those people with and without comorbid cannabis abuse: the implications for eye movement research in schizophrenia. Acta neuropsychiatrica. vol 18. issue 6. 2016-07-12. PMID:27397345. |
01-04 visual scanpath comparisons between those people with and without comorbid cannabis abuse: the implications for eye movement research in schizophrenia. |
2016-07-12 |
2023-08-13 |
Not clear |
| Brian D Power, Milan Dragovic, Johanna C Badcock, Vera A Morgan, David Castle, Assen Jablensky, Nikos C Stefani. No additive effect of cannabis on cognition in schizophrenia. Schizophrenia research. vol 168. issue 1-2. 2016-07-06. PMID:26235754. |
no additive effect of cannabis on cognition in schizophrenia. |
2016-07-06 |
2023-08-13 |
Not clear |
| M Smeerdijk, R Keet, B van Raaij, M Koeter, D Linszen, L de Haan, G Schipper. Motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up. Psychological medicine. vol 45. issue 13. 2016-06-13. PMID:25959502. |
motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up. |
2016-06-13 |
2023-08-13 |
Not clear |
| M Smeerdijk, R Keet, B van Raaij, M Koeter, D Linszen, L de Haan, G Schipper. Motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up. Psychological medicine. vol 45. issue 13. 2016-06-13. PMID:25959502. |
this follow-up of a randomized trial examined whether an intervention for parents, based on motivational interviewing and interaction skills (family motivational intervention, fmi), was more effective than routine family support (rfs) in reducing cannabis use in patients with recent-onset schizophrenia. |
2016-06-13 |
2023-08-13 |
Not clear |
| Natalia Brzozowska, Kong M Li, Xiao Suo Wang, Jessica Booth, Jordyn Stuart, Iain S McGregor, Jonathon C Arnol. ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ. vol 4. 2016-06-03. PMID:27257556. |
cannabidiol (cbd) is currently being investigated as a novel therapeutic for the treatment of cns disorders like schizophrenia and epilepsy. |
2016-06-03 |
2023-08-13 |
mouse |
| Danielle Impey, Nicole El-Marj, Andrea Parks, Joelle Choueiry, Derek Fisher, Verner J Knot. Mismatch negativity in tobacco-naïve cannabis users and its alteration with acute nicotine administration. Pharmacology, biochemistry, and behavior. vol 136. 2016-05-17. PMID:26188167. |
chronic cannabis use may interact with factors, such as age of onset of cannabis use, family history, and genetic factors, to elicit schizophrenia (sz)-like symptoms, including sensory and cognitive deficits. |
2016-05-17 |
2023-08-13 |
human |
| Amresh Shrivastava, Megan Johnston, Kristen Terpstra, Yves Burea. Pathways to psychosis in cannabis abuse. Clinical schizophrenia & related psychoses. vol 9. issue 1. 2016-05-12. PMID:23491968. |
in this review, we attempt to understand the neurobiological pathways that link cannabis use to schizophrenia. |
2016-05-12 |
2023-08-12 |
Not clear |
| Amresh Shrivastava, Megan Johnston, Kristen Terpstra, Yves Burea. Pathways to psychosis in cannabis abuse. Clinical schizophrenia & related psychoses. vol 9. issue 1. 2016-05-12. PMID:23491968. |
this has been an area of great debate; despite similarities between cannabis users and schizophrenia patients, the evidence is not sufficient to establish cause-and-effect. |
2016-05-12 |
2023-08-12 |
Not clear |
| Amresh Shrivastava, Megan Johnston, Kristen Terpstra, Yves Burea. Pathways to psychosis in cannabis abuse. Clinical schizophrenia & related psychoses. vol 9. issue 1. 2016-05-12. PMID:23491968. |
there have been advances in the understanding of the mechanisms of cannabis dependence as well as the role of the cannabinoid system in the development of psychosis and schizophrenia. |
2016-05-12 |
2023-08-12 |
Not clear |
| Amresh Shrivastava, Megan Johnston, Kristen Terpstra, Yves Burea. Pathways to psychosis in cannabis abuse. Clinical schizophrenia & related psychoses. vol 9. issue 1. 2016-05-12. PMID:23491968. |
in order to better understand these associations, this paper will show common neurobiological and neuroanatomical changes as well as common cognitive dysfunction in cannabis users and patients of schizophrenia. |
2016-05-12 |
2023-08-12 |
Not clear |
| Matthew J Smith, Derin J Cobia, James L Reilly, Jodi M Gilman, Andrea G Roberts, Kathryn I Alpert, Lei Wang, Hans C Breiter, John G Csernansk. Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. Hippocampus. vol 25. issue 9. 2016-05-12. PMID:25760303. |
cannabis use has been associated with episodic memory (em) impairments and abnormal hippocampus morphology among both healthy individuals and schizophrenia subjects. |
2016-05-12 |
2023-08-13 |
human |
| Matthew J Smith, Derin J Cobia, James L Reilly, Jodi M Gilman, Andrea G Roberts, Kathryn I Alpert, Lei Wang, Hans C Breiter, John G Csernansk. Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. Hippocampus. vol 25. issue 9. 2016-05-12. PMID:25760303. |
we examined differences in hippocampus morphology between control and schizophrenia subjects with and without a past (not current) cannabis use disorder (cud). |
2016-05-12 |
2023-08-13 |
human |